CA Patent

CA3019182A1 — Hck as a therapeutic target in myd88 mutated diseases

Assigned to Dana Farber Cancer Institute Inc · Expires 2017-11-02 · 9y expired

What this patent protects

Methods of treatment of conditions or diseases associated with myeloid differentiation primary response (MYD88) protein using a selective HCK inhibitor are provided herein.

USPTO Abstract

Methods of treatment of conditions or diseases associated with myeloid differentiation primary response (MYD88) protein using a selective HCK inhibitor are provided herein.

Drugs covered by this patent

Patent Metadata

Patent number
CA3019182A1
Jurisdiction
CA
Classification
—
Expires
2017-11-02
Drug substance claim
No
Drug product claim
No
Assignee
Dana Farber Cancer Institute Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.